Literature DB >> 29107268

Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.

Stacy Loeb1, Hasan Dani2.   

Abstract

This article describes markers used for prostate biopsy decisions, including prostrate-specific antigen (PSA), free PSA, the prostate health index, 4Kscore, PCA3, and ConfirmMDx. It also summarizes the use of nomograms combining multiple variables for prostate cancer detection.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarkers; Nomograms; Prostate biopsy; Prostate cancer; Prostate-specific antigen

Mesh：

Substances：

Year:  2017        PMID： 29107268      PMCID： PMC6004126          DOI： 10.1016/j.ucl.2017.07.001

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN： 0094-0143            Impact factor:   2.241


  71 in total

1.  Reevaluating PSA Testing Rates in the PLCO Trial.

Authors:  Jonathan E Shoag; Sameer Mittal; Jim C Hu
Journal:  N Engl J Med       Date:  2016-05-05       Impact factor: 91.245

Review 2.  Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer.

Authors:  Linda A Bradley; Glenn E Palomaki; Steven Gutman; David Samson; Naomi Aronson
Journal:  J Urol       Date:  2013-03-29       Impact factor: 7.450

3.  PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.

Authors:  Marc C Gittelman; Bernard Hertzman; James Bailen; Thomas Williams; Isaac Koziol; Ralph Jonathan Henderson; Mitchell Efros; Mohamed Bidair; John F Ward
Journal:  J Urol       Date:  2013-02-14       Impact factor: 7.450

4.  PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.

Authors:  Sheila M J Aubin; Jennifer Reid; Mark J Sarno; Amy Blase; Jacqueline Aussie; Harry Rittenhouse; Roger Rittmaster; Gerald L Andriole; Jack Groskopf
Journal:  J Urol       Date:  2010-09-17       Impact factor: 7.450

5.  The prostate health index selectively identifies clinically significant prostate cancer.

Authors:  Stacy Loeb; Martin G Sanda; Dennis L Broyles; Sanghyuk S Shin; Chris H Bangma; John T Wei; Alan W Partin; George G Klee; Kevin M Slawin; Leonard S Marks; Ron H N van Schaik; Daniel W Chan; Lori J Sokoll; Amabelle B Cruz; Isaac A Mizrahi; William J Catalona
Journal:  J Urol       Date:  2014-11-15       Impact factor: 7.450

6.  Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy.

Authors:  Giovanni Lughezzani; Massimo Lazzeri; Alessandro Larcher; Giuliana Lista; Vincenzo Scattoni; Andrea Cestari; Nicoló Maria Buffi; Vittorio Bini; Giorgio Guazzoni
Journal:  J Urol       Date:  2012-08-15       Impact factor: 7.450

7.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

8.  Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.

Authors:  Claire de la Calle; Dattatraya Patil; John T Wei; Douglas S Scherr; Lori Sokoll; Daniel W Chan; Javed Siddiqui; Juan Miguel Mosquera; Mark A Rubin; Martin G Sanda
Journal:  J Urol       Date:  2015-01-28       Impact factor: 7.450

9.  The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort.

Authors:  Hiromi Hirama; Mikio Sugimoto; Kazuto Ito; Taizo Shiraishi; Yoshiyuki Kakehi
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-19       Impact factor: 4.553

10.  A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.

Authors:  Andrew J Vickers; Angel M Cronin; Gunnar Aus; Carl-Gustav Pihl; Charlotte Becker; Kim Pettersson; Peter T Scardino; Jonas Hugosson; Hans Lilja
Journal:  BMC Med       Date:  2008-07-08       Impact factor: 8.775
View more
  2 in total

1.  Redesigning Prostate Cancer Screening Strategies to Reduce Overdiagnosis.

Authors:  Andrew J Vickers
Journal:  Clin Chem       Date:  2018-10-01       Impact factor: 8.327

2.  Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men: The Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study.

Authors:  Lars Boesen; Nis Nørgaard; Vibeke Løgager; Ingegerd Balslev; Rasmus Bisbjerg; Karen-Cecilie Thestrup; Mads D Winther; Henrik Jakobsen; Henrik S Thomsen
Journal:  JAMA Netw Open       Date:  2018-06-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.